The Best Could Be Yet to Come for Novo Nordisk and Ozempic

Novo Nordisk's stock may look expensive but not if you focus on the long term.Ozempic has become the big name associated with weight loss. Although there are other competing drugs which could take market share from it in the future, the diabetes treatment has become well known on social media for its ability to help people lose weight. And that success has played a big role in Novo Nordisk (NVO 0.14%) becoming one of the most valuable healthcare companies in the world.But as well as things are going for the ...